BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38859866)

  • 1. The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression.
    Li GH; Miao Y; Chen H; Xue MF; Wang JY; Zhang JW; Yi ZF; Sun ZL
    Am J Cancer Res; 2024; 14(5):2072-2087. PubMed ID: 38859866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
    Ishikawa C; Mori N
    Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1.
    Dong B; Jaeger AM; Hughes PF; Loiselle DR; Hauck JS; Fu Y; Haystead TA; Huang J; Thiele DJ
    Sci Transl Med; 2020 Dec; 12(574):. PubMed ID: 33328331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux.
    Samarasinghe B; Wales CT; Taylor FR; Jacobs AT
    Biochem Pharmacol; 2014 Feb; 87(3):445-55. PubMed ID: 24291777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
    Huang M; Dong W; Xie R; Wu J; Su Q; Li W; Yao K; Chen Y; Zhou Q; Zhang Q; Li W; Cheng L; Peng S; Chen S; Huang J; Chen X; Lin T
    Cancer Commun (Lond); 2022 May; 42(5):447-470. PubMed ID: 35434944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to HSP90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels.
    Li N; Wang T; Li Z; Ye X; Deng B; Zhuo S; Yao P; Yang M; Mei H; Chen X; Zhu T; Chen S; Wang H; Wang J; Le Y
    Cancer Biol Med; 2019 May; 16(2):220-233. PubMed ID: 31516744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.
    Yoon YJ; Kim JA; Shin KD; Shin DS; Han YM; Lee YJ; Lee JS; Kwon BM; Han DC
    J Biol Chem; 2011 Jan; 286(3):1737-47. PubMed ID: 21078672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
    Isermann T; Schneider KL; Wegwitz F; De Oliveira T; Conradi LC; Volk V; Feuerhake F; Papke B; Stintzing S; Mundt B; Kühnel F; Moll UM; Schulz-Heddergott R
    bioRxiv; 2024 Feb; ():. PubMed ID: 38464125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine.
    Howard TP; Oberlick EM; Rees MG; Arnoff TE; Pham MT; Brenan L; DoCarmo M; Hong AL; Kugener G; Chou HC; Drosos Y; Mathias KM; Ramos P; Seashore-Ludlow B; Giacomelli AO; Wang X; Freeman BB; Blankenship K; Hoffmann L; Tiv HL; Gokhale PC; Johannessen CM; Stewart EA; Schreiber SL; Hahn WC; Roberts CWM
    Clin Cancer Res; 2020 Sep; 26(18):4995-5006. PubMed ID: 32631955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights from yeast into whether the inhibition of heat shock transcription factor (Hsf1) by rapamycin can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor.
    Millson SH; Piper PW
    Oncotarget; 2014 Jul; 5(13):5054-64. PubMed ID: 24970820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.
    Chen Y; Chen J; Yu J; Yang G; Temple E; Harbinski F; Gao H; Wilson C; Pagliarini R; Zhou W
    J Biol Chem; 2014 Jul; 289(27):18914-27. PubMed ID: 24831003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective killing of cancer cells by small molecules targeting heat shock stress response.
    Zhang D; Zhang B
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1509-14. PubMed ID: 27553278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters.
    Kim JA; Kim Y; Kwon BM; Han DC
    J Biol Chem; 2013 Oct; 288(40):28713-26. PubMed ID: 23983126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition.
    Pastorek M; Muller P; Coates PJ; Vojtesek B
    PLoS One; 2018; 13(8):e0202758. PubMed ID: 30138434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of inhibitors of HSF1 functional activity by high-content target-based screening.
    Au Q; Zhang Y; Barber JR; Ng SC; Zhang B
    J Biomol Screen; 2009 Dec; 14(10):1165-75. PubMed ID: 19820069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner.
    Chai RC; Kouspou MM; Lang BJ; Nguyen CH; van der Kraan AG; Vieusseux JL; Lim RC; Gillespie MT; Benjamin IJ; Quinn JM; Price JT
    J Biol Chem; 2014 May; 289(19):13602-14. PubMed ID: 24692538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective.
    Workman P
    Adv Exp Med Biol; 2020; 1243():163-179. PubMed ID: 32297218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer.
    Rossi A; Ciafrè S; Balsamo M; Pierimarchi P; Santoro MG
    Cancer Res; 2006 Aug; 66(15):7678-85. PubMed ID: 16885369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of HSF1 and DYRK2 impedes cancer progression.
    Tandon V; Moreno R; Allmeroth K; Quinn J; Wiley SE; Nicely LG; Denzel MS; Edwards J; de la Vega L; Banerjee S
    Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36622366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.